Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2004; 44:2315-2325, doi:10.1016/j.jacc.2004.05.088
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mogensen, J.
Right arrow Articles by McKenna, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mogensen, J.
Right arrow Articles by McKenna, W. J.

Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy

Jens Mogensen, MD, PhD*,*, Ross T. Murphy, MD*, Toru Kubo, MD*,{dagger}, Ajay Bahl, MD*, James C. Moon, MD{ddagger}, Ib C. Klausen, MD{ddagger}, Perry M. Elliott, MD* and William J. McKenna, MD*

* Department of Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom
{dagger} Department of Medicine and Geriatrics, Kochi Medical School, Kochi, Japan
{ddagger} Department of Cardiology, Skejby University Hospital, Aarhus, Denmark



View larger version (17K):

[in a new window]
 
Figure 1 Distribution of mutations and amino acid polymorphisms in TNNI3 identified in the present study. The initial 280 patients with hypertrophic cardiomyopathy underwent mutation analysis in all protein-encoding exons of TNNI3 whereas the remaining 468 were investigated in exons 5, 7, and 8 only. Novel mutations are in italics. Exons are indicated by boxes, and interaction sites with other thin filament proteins are indicated with different patterns. Dotted patterns = troponin T-binding domain, residue 61 to 112; small slash pattern = troponin C-binding domain, residue, 113 to 164; large slash pattern = actin-binding domain, residue 130 to 148; 173 to 181.

 



View larger version (39K):

[in a new window]
 
Figure 2 Pedigrees of hypertrophic cardiomyopathy (HCM) families with TNNI3 mutations. Squares = male family members; circles = female family members; symbols with slash = deceased individuals; open symbols = unaffected individuals; solid symbols = individuals affected; question mark = unknown clinical status; plus sign = presence of mutation; minus sign = absence of mutation. No clinical data were available in H375, II:6, but she was assumed to have HCM due to the fact that she was an obligate mutation carrier and had symptoms of disease preceding her unexplained sudden death.

 


View larger version (86K):

[in a new window]
 
Figure 3 Cine cardiac magnetic resonance (CMR) images of hypertrophic cardiomyopathy (HCM) patients with TNNI3 mutations (30). A wide range of HCM was present including: (A) asymmetrical anteroseptal hypertrophy (Arg162Gln), (B) apical hypertrophy (Arg162Gln), (C) midcavity obstruction (Arg145Trp), (D) extreme biventricular hypertrophy (Arg141Gln), (E) "end-stage dilation" (Arg186Gln), and (F) restrictive cardiomyopathy in a child six years of age (de novo Lys178Glu) as recently reported (did not participate in this study) (32). CMR images: (A and B) From left to right: four-chamber, basal short-axis, and apical short-axis, all in diastole; (C to F) four-chamber systole, four-chamber diastole, short-axis diastole. (A and B) first image = four-chamber view, diastole; second image = cross-sectional view, papillary muscle level, diastole; third image = cross-sectional view, apical level, diastole. (D to F) first image = four-chamber view, systole; second image = four-chamber view, diastole; third image = papillary muscle level, diastole. LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle.

 


View larger version (99K):

[in a new window]
 
Figure 4 Electrocardiograms of asymptomatic mutation carriers with normal left ventricular (LV) wall thickness on echocardiography. (A) H136, III:2 age 17 years: Q waves in III, V4 through V6; LV hypertrophy. (B) H15, III:2, age 36 years: left axis; Q waves in II, III, aVF; ST-segment abnormalities in II, III, V2 through V6. (C) H25, II:3, age 72 years: left axis; ST-segment abnormalities in I, aVL, V5 through V6; intraventricular conduction delay, V3 through V4.

 


View larger version (14K):

[in a new window]
 
Figure 5 Phenotypic status and age at first clinical evaluation of all individuals identified with TNNI3 mutations including probands and clinically affected and unaffected mutation carriers. The mean age at first clinical evaluation of affected individuals (probands + affected relatives) was 39.9 years (standard deviation: 17.7) and for unaffected relatives 39.6 years (standard deviation: 18.2). Solid bars = probands; checkered bars = affected relatives with hypertrophic cardiomyopathy; open bars = unaffected relatives.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement